Subject:
- Active Substance: Etranacogen dezaparvovec
- Name: Hemgenix®
- Therapeutic area: Hemophilia B
- Pharmaceutical company: CSL Behring GmbH
Time table:
- Start: 01.05.2023
- Publication of assessment: 01.08.2023
- End of public hearing: 22.08.2023
- Final decision by G-BA: middle of October 2023
Comparative therapy:
-
No comparative therapy due to orphan drug designation